Postintravitreal Injection Endophthalmitis: Incidence, Characteristics, Management, and Outcome

Purpose. Postintravitreal injection (IVI) endophthalmitis is a rare but devastating complication. Herein, we report the incidence ,and clinical and microbiological characteristics, as well as the visual outcome, in IVIs endophthalmitis in two medical centers. Methods. All patients undergoing intravi...

Full description

Saved in:
Bibliographic Details
Main Authors: Bar Davidov, Avi Ohayon, Omer Trivizki, Shulamit Schwartz, Shiri Shulman
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2023/9212524
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849738302866849792
author Bar Davidov
Avi Ohayon
Omer Trivizki
Shulamit Schwartz
Shiri Shulman
author_facet Bar Davidov
Avi Ohayon
Omer Trivizki
Shulamit Schwartz
Shiri Shulman
author_sort Bar Davidov
collection DOAJ
description Purpose. Postintravitreal injection (IVI) endophthalmitis is a rare but devastating complication. Herein, we report the incidence ,and clinical and microbiological characteristics, as well as the visual outcome, in IVIs endophthalmitis in two medical centers. Methods. All patients undergoing intravitreal injections between 1/2018 and 12/2019 in two large medical centers were analyzed for post-IVI endophthalmitis. Results. Of the total of 51,356 IVIs performed, 23 cases of post-IVI endophthalmitis were diagnosed, yielding an overall incidence of 0.045%. The median interval from IVI to symptoms onset was 2 days (IQR: 1–5). Cultures were positive in 56% of the cases (100% Gram-positive bacteria and 76% coagulase-negative staphylococcus). Parameters associated with higher culture-positive rates included samples taken during vitrectomy, WBC on vitreous smear, the number of IVIs in the 12 months prior to presentation, and the time interval from last IVI to diagnostic sampling. At 6- and 12-month follow-up, the median change in VA (logMAR) was −1.10 (IQR: (−1.32)–(−0.40)) and −1.02 (IQR: (−1.10)–(−0.30)), respectively. Younger age and better BCVA at presentation were associated with better VA outcome, while positive culture result and systemic steroids treatment were each associated with the worse visual outcome. We found no difference in visual outcomes between PPV and TAI as a primary procedure. Conclusion. Post-IVI endophthalmitis is a rare complication, and most patients do not regain their initial VA. Certain parameters (clinical, microbiological, and therapeutic) may help anticipate the outcome and guide decision making regarding diagnosis and treatment.
format Article
id doaj-art-fd467479ac984d8583dda3edbb30555d
institution DOAJ
issn 2090-0058
language English
publishDate 2023-01-01
publisher Wiley
record_format Article
series Journal of Ophthalmology
spelling doaj-art-fd467479ac984d8583dda3edbb30555d2025-08-20T03:06:39ZengWileyJournal of Ophthalmology2090-00582023-01-01202310.1155/2023/9212524Postintravitreal Injection Endophthalmitis: Incidence, Characteristics, Management, and OutcomeBar Davidov0Avi Ohayon1Omer Trivizki2Shulamit Schwartz3Shiri Shulman4Division of OphthalmologyDivision of OphthalmologyDivision of OphthalmologyDivision of OphthalmologyOpthalmology InstitutePurpose. Postintravitreal injection (IVI) endophthalmitis is a rare but devastating complication. Herein, we report the incidence ,and clinical and microbiological characteristics, as well as the visual outcome, in IVIs endophthalmitis in two medical centers. Methods. All patients undergoing intravitreal injections between 1/2018 and 12/2019 in two large medical centers were analyzed for post-IVI endophthalmitis. Results. Of the total of 51,356 IVIs performed, 23 cases of post-IVI endophthalmitis were diagnosed, yielding an overall incidence of 0.045%. The median interval from IVI to symptoms onset was 2 days (IQR: 1–5). Cultures were positive in 56% of the cases (100% Gram-positive bacteria and 76% coagulase-negative staphylococcus). Parameters associated with higher culture-positive rates included samples taken during vitrectomy, WBC on vitreous smear, the number of IVIs in the 12 months prior to presentation, and the time interval from last IVI to diagnostic sampling. At 6- and 12-month follow-up, the median change in VA (logMAR) was −1.10 (IQR: (−1.32)–(−0.40)) and −1.02 (IQR: (−1.10)–(−0.30)), respectively. Younger age and better BCVA at presentation were associated with better VA outcome, while positive culture result and systemic steroids treatment were each associated with the worse visual outcome. We found no difference in visual outcomes between PPV and TAI as a primary procedure. Conclusion. Post-IVI endophthalmitis is a rare complication, and most patients do not regain their initial VA. Certain parameters (clinical, microbiological, and therapeutic) may help anticipate the outcome and guide decision making regarding diagnosis and treatment.http://dx.doi.org/10.1155/2023/9212524
spellingShingle Bar Davidov
Avi Ohayon
Omer Trivizki
Shulamit Schwartz
Shiri Shulman
Postintravitreal Injection Endophthalmitis: Incidence, Characteristics, Management, and Outcome
Journal of Ophthalmology
title Postintravitreal Injection Endophthalmitis: Incidence, Characteristics, Management, and Outcome
title_full Postintravitreal Injection Endophthalmitis: Incidence, Characteristics, Management, and Outcome
title_fullStr Postintravitreal Injection Endophthalmitis: Incidence, Characteristics, Management, and Outcome
title_full_unstemmed Postintravitreal Injection Endophthalmitis: Incidence, Characteristics, Management, and Outcome
title_short Postintravitreal Injection Endophthalmitis: Incidence, Characteristics, Management, and Outcome
title_sort postintravitreal injection endophthalmitis incidence characteristics management and outcome
url http://dx.doi.org/10.1155/2023/9212524
work_keys_str_mv AT bardavidov postintravitrealinjectionendophthalmitisincidencecharacteristicsmanagementandoutcome
AT aviohayon postintravitrealinjectionendophthalmitisincidencecharacteristicsmanagementandoutcome
AT omertrivizki postintravitrealinjectionendophthalmitisincidencecharacteristicsmanagementandoutcome
AT shulamitschwartz postintravitrealinjectionendophthalmitisincidencecharacteristicsmanagementandoutcome
AT shirishulman postintravitrealinjectionendophthalmitisincidencecharacteristicsmanagementandoutcome